NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study of Three Anti-HIV Drug Combinations in Patients Who Have Taken Amprenavir

Phase 2

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-11-04

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 94

Registration Number: NCT00001095

Locations: 🇺🇸
St Louis Regional Hosp / St Louis Regional Med Ctr, Saint Louis, Missouri, United States
🇺🇸
Univ of North Carolina, Chapel Hill, North Carolina, United States
🇺🇸
Univ of Southern California / LA County USC Med Ctr, Los Angeles, California, United States

and more 9 locations

The Effectiveness of Ritonavir Plus Zidovudine Plus Lamivudine in HIV-Infected Patients

Not Applicable

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-11-04

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 55

Registration Number: NCT00001075

Locations: 🇺🇸
University of Colorado Hospital CRS, Aurora, Colorado, United States
🇺🇸
Rush Univ. Med. Ctr. ACTG CRS, Chicago, Illinois, United States
🇺🇸
Case CRS, Cleveland, Ohio, United States

A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV (vCP205) in HIV-1 Uninfected Adult Volunteers

Phase 1

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-11-04

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 76

Registration Number: NCT00001055

Locations: 🇺🇸
UAB AVEG, Birmingham, Alabama, United States
🇺🇸
Univ. of Rochester AVEG, Rochester, New York, United States
🇺🇸
UW - Seattle AVEG, Seattle, Washington, United States

and more 3 locations

A Study of Foscarnet in the Treatment of HIV Infection in Patients Who Have Taken Zidovudine for a Long Time

Phase 1

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-11-04

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 12

Registration Number: NCT00001002

Locations: 🇺🇸
University of Minnesota, ACTU, Minneapolis, Minnesota, United States
🇺🇸
Unc Aids Crs, Chapel Hill, North Carolina, United States

A Randomized, Placebo-Controlled, Double-Blinded Phase I Safety and Immunogenicity Trial of Recombinant Envelope Protein, HIV-1 SF-2 rgp120 (BIOCINE), Combined With MF59 in HIV-1 Uninfected Adult Volunteers

Phase 1

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-11-04

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 30

Registration Number: NCT00000832

Locations: 🇺🇸
JHU AVEG, Pittsburgh, Pennsylvania, United States
🇺🇸
UAB AVEG, Birmingham, Alabama, United States
🇺🇸
Univ. of Rochester AVEG, Rochester, New York, United States

and more 1 locations

A Study of Stem Cells and Filgrastim

Not Applicable

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-11-04

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 24

Registration Number: NCT00001071

Locations: 🇺🇸
UCLA CARE Center CRS, Los Angeles, California, United States
🇺🇸
University of Colorado Hospital CRS, Aurora, Colorado, United States

A Phase I Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of HIV-1 Recombinant Envelope Glycoprotein gp160

Phase 1

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-11-04

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 72

Registration Number: NCT00000745

Locations: 🇺🇸
JHU AVEG, Pittsburgh, Pennsylvania, United States
🇺🇸
Vanderbilt Univ. Hosp. AVEG, Nashville, Tennessee, United States

Active Immunization of Asymptomatic, HIV-Infected Individuals With Recombinant GP160 HIV-1 Antigen: A Phase I/II Study of Immunogenicity and Toxicity

Phase 1

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-11-04

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 52

Registration Number: NCT00000977

Locations: 🇺🇸
NY Univ. HIV/AIDS CRS, New York, New York, United States
🇺🇸
Stanford CRS, Palo Alto, California, United States

A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia Derived HIV-1 Recombinant Envelope Glycoprotein (gp160) of Human Immunodeficiency Virus: Evaluation of a 200-mcg Dose

Phase 1

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-11-04

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 25

Registration Number: NCT00001056

Locations: 🇺🇸
Vanderbilt Univ. Hosp. AVEG, Nashville, Tennessee, United States
🇺🇸
St. Louis Univ. School of Medicine AVEG, Saint Louis, Missouri, United States
🇺🇸
Univ. of Rochester AVEG, Rochester, New York, United States

Subcutaneously Administered Aldesleukin ( Interleukin-2; IL-2 ) Therapy in HIV-Infected Patients

Phase 1

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-11-03

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 78

Registration Number: NCT00000821

Locations: 🇺🇸
Natl Inst of Allergy & Infect Dis / Cln Ctr, Bethesda, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy